MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

Core Insights - MaxCyte, Inc. has appointed Parmeet Ahuja as Chief Financial Officer effective March 30, 2026, succeeding Douglas Swirsky [1] - Ahuja brings over 20 years of finance leadership experience, particularly in the life sciences sector, having previously served as Vice President of Investor Relations at Agilent Technologies [2] - Ahuja expressed enthusiasm about joining MaxCyte, highlighting the transformative potential of the company's electroporation platform for the Cell and Gene Therapy industry [3] Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [3] - The company utilizes its Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services to enable precise and scalable cell engineering [3] - MaxCyte has over 25 years of experience in cell engineering, contributing to the future of medicine [3]